



Final Appraisal Recommendation

Advice No: 4214 – December 2014

Infliximab (Inflectra[®]▼) 100 mg powder for concentrate for solution for infusion

Submission by Hospira UK Ltd

Recommendation of AWMSG

Infliximab (Inflectra[®]▼) is recommended as an option for restricted use within NHS Wales.

Infliximab (Inflectra[®]▼) should be prescribed within its licensed indications in accordance with NICE or AWMSG guidance for infliximab (Remicade[®]), the reference product.

Infliximab (Inflectra[®]▼) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- Please refer to the NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology.
- In accordance with EMA guidance, the licence for the use of infliximab (Inflectra[®]▼) in rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis was granted on the basis of assumed bioequivalence.
- Due to the potential for small differences between biosimilars from different manufacturers and/or the reference product infliximab (Remicade[®]), post-marketing pharmacovigilance is essential and will be facilitated by the Risk Management Plan.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2253), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Marketing authorisation holder on first issue	Hospira UK Ltd
Date of first issue	December 2014
Last reviewed	March 2018

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 4214:
Infliximab (Inflectra[®]) 100 mg powder for concentrate for solution for infusion. December 2014.